Partnering in Digital Science AH JANUARY 2025 CORP_0.pdf Partnering in Digital Science AH JANUARY 2025 CORP_0.pdf Provides a summary of animal health partnering interests in digital science.
Partnering in Technologies AH JANUARY 2025 CORP.pdf Partnering in Technologies AH JANUARY 2025 CORP.pdf A summary of Boehringer Ingelheim's technology partnering interests in animal health
Partnering in Pain & Mobility AH JANUARY 2025 CORP.pdf Partnering in Pain & Mobility AH JANUARY 2025 CORP.pdf Summary of Boehringer Ingelheim Animal Health partnering interests in Pain & Mobility
Partnering in Oral Health AH JANUARY 2025 CORP.pdf Partnering in Oral Health AH JANUARY 2025 CORP.pdf Summary of Boehringer Ingelheim Animal Health partnering interests in Oral Health
Partnering in Oncology AH JANUARY 2025 CORP_1.pdf Partnering in Oncology AH JANUARY 2025 CORP_1.pdf Provides a summary of Boehringer Ingelheim's animal health partnering interests in Oncology.
Partnering in Immunology & Inflammation AH JANUARY 2025 CORP.pdf Partnering in Immunology & Inflammation AH JANUARY 2025 CORP.pdf Summary of Boehringer Ingelheim Animal Health partnering interests in Immunology & Inflammation
Partnering in CNS Diseases AH JANUARY 2025 CORP.pdf Partnering in CNS Diseases AH JANUARY 2025 CORP.pdf Summary of animal health partnering interests in central nervous system diseases
Partnering in Cardiometabolic Diseases AH JANUARY 2025 CORP.pdf Partnering in Cardiometabolic Diseases AH JANUARY 2025 CORP.pdf Summary of animal health partnering interests in cardiometabolic diseases.
Partnering in Parasitology AH JANUARY 2025 CORP.pdf Partnering in Parasitology AH JANUARY 2025 CORP.pdf Summary of Boehringer Ingelheim's animal health partnering interests in parasitology
Partnering in Viral Diseases AH JANUARY 2025 CORP Partnering in Viral Diseases AH JANUARY 2025 CORP A summary of Boehringer Ingelheim's partnering interests in viral diseases in animal health
Partnering in Bacterial Diseases AH JANUARY 2025 CORP Partnering in Bacterial Diseases AH JANUARY 2025 CORP Provides a summary of the animal health partnering interests in bacterial diseases.
Animal Health partnering interests Animal Health partnering interests Overview of Animal Health partnering interests
勃林格殷格翰两项SIRPα抑制剂早期临床研究即将亮相 2025 ASCO年会 勃林格殷格翰两项SIRPα抑制剂早期临床研究即将亮相 2025 ASCO年会 勃林格殷格翰两项SIRPα抑制剂早期临床研究即将亮相 2025 ASCO年会
Outlook for Partnering Animal Health 2025 Outlook for Partnering Animal Health 2025 A summary of Boehringer Ingelheim's partnering approach and priorities in animal health for 2025 .
重磅!勃林格殷格翰新一代溶栓药物美通立®在华获批,用于治疗急性缺血性卒中 重磅!勃林格殷格翰新一代溶栓药物美通立®在华获批,用于治疗急性缺血性卒中 重磅!勃林格殷格翰新一代溶栓药物美通立®在华获批,用于治疗急性缺血性卒中
全球 III 期试验显示nerandomilast可减缓IPF和PPF患者肺功能下降,且停药率与安慰剂相似 全球 III 期试验显示nerandomilast可减缓IPF和PPF患者肺功能下降,且停药率与安慰剂相似 全球 III 期试验显示nerandomilast可减缓IPF和PPF患者肺功能下降,且停药率与安慰剂相似
喜讯!勃林格殷格翰在研疗法nerandomilast再获CDE优先审评, 加速惠及中国进展性肺纤维化患者 喜讯!勃林格殷格翰在研疗法nerandomilast再获CDE优先审评, 加速惠及中国进展性肺纤维化患者 喜讯!勃林格殷格翰在研疗法nerandomilast再获CDE优先审评, 加速惠及中国进展性肺纤维化患者
再拓新程!勃林格殷格翰递交肺纤维化创新疗法nerandomilast新适应症上市申请 再拓新程!勃林格殷格翰递交肺纤维化创新疗法nerandomilast新适应症上市申请 再拓新程!勃林格殷格翰递交肺纤维化创新疗法nerandomilast新适应症上市申请
重磅!Zongertinib在HER2突变晚期非小细胞肺癌患者中展现持久且具有临床意义的疗效 重磅!Zongertinib在HER2突变晚期非小细胞肺癌患者中展现持久且具有临床意义的疗效 重磅!Zongertinib在HER2突变晚期非小细胞肺癌患者中展现持久且具有临床意义的疗效
请扫码关注我们
勃林格殷格翰官方
勃林格殷格翰HR
勃林格殷格翰动保